Claims for Patent: 5,422,097

Summary for Patent: 5,422,097

Title:	Combined antiviral and antimediator treatment of common colds
Abstract:	The common cold is best treated by providing a combination of antiviral agents and antiinflammatory compounds to a patient infected with a cold virus. An antiviral agent and two antiinflammatory compounds given to a person infected with a cold virus simultaneously reduces the likelihood of a cold developing and the amount and duration of viral shedding, as well as substantially reduces the severity of individual cold symptoms and the overall number and severity of cold symptoms. Supplementing the activity of the combined antiviral and antiinflammatory agents with such compounds as antihistamines and alpha agonists results in suprisingly good nasal benefits. The combination therapy, termed COVAM therapy, is well tolerated and has no evidence of short-term toxicity.
Inventor(s):	Gwaltney, Jr.; Jack M. (Free Union, VA)
Assignee:	University of Virginia (Charlottesville, VA) Center for Innovative Technology (Herndon, VA)
Application Number:	08/112,588
Patent Claims:	1. A kit for combatting the common cold, comprising: a therapeutically effective amount of at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses; and a therapeutically effective amount of at least one antiinflammatory compound specific for inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathways, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, and the kinin pathway. 2. A kit as recited in claim 1 wherein said antinflammatory compound is selected from the group consisting of ipratropium, atropine methonitrate, exogenous opioid agonists, alpha adrenergic agonists, antihistamines including chlorpheniramine, prostaglandin blockers and antagonists, leukotriene blockers and antagonists, parasympathetic blockers and antagonists, interleukin blockers and antagonists, and nonsteroidal antiinflammatory agents including naproxen ibuprophen. 3. A kit as recited in claim 1 wherein said antiviral agent is selected from the group consisting of inteferons, interferon inducers, capsid binding agents, benzoimidazoles, 1'-methyl spiro(adamantane-2,3-pyrrolidine)maleate, isatin thiosemicarbazone, fusidic acid, substituted trizainoindoles, 2,6-diphenyl-3-methyl-2,3-dihydroimidazothiazole, 3-alpha-naphthl-5-diethylcarbamoyl-1,2,4-oxadiazole, oxolinic acid, isoquinolines, 1-p-chlorophenyl-3-(m-3-isobutylguanidinophenyl)urea hydrochloride, anti ICAM-1 antibody and other viral receptor antibodies, synthetic ICA-1 and other synthetic viral receptors, amantadine, rimantadine, and ribavirin. 4. A kit as recited in claim 1 further comprising a therapeutically effective amount of at least one antihistamine compound which is different from said antiinflammatory compound. 5. A kit as recited in claim 4 wherein said antihistamine is selected from the group consisting of chlorpheniramine, diphenylhydramine, brompheniramine, clemastine, and terfenadine. 6. A method as recited in claim 1 further comprising a therapeutically effective amount of at least one alpha agonist compound which is different from said antiinflammatory compound. 7. A kit as recited in claim 6 wherein said alpha agonist is selected from the group consisting of phenylephrine, pseudoephedrine, phenylpropanolamine, oxymetazoline, and xylometazoline. 8. A kit for combatting the common cold, comprising: a therapeutically effective amount of at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses; and a therapeutically effective amount of at least two antiinflammatory compounds specific for at least two different inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathways, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, and the kinin pathway. 9. A kit as recited in claim 8 wherein said antiviral agent is interferon .alpha.2, and wherein said antiinflammatory agents include naproxen and ipratropium. 10. A kit as recited in claim 8 wherein at least one of said antiviral agent and said antiinflammatory compounds is present in orally deliverable form and at least one of said antiviral agent and said antiinflammatory compounds is present in nasally deliverable form. 11. A kit as recited in claim 8 wherein said antinflammatory compounds are selected from the group consisting of ipratropium, atropine methonitrate, exogenous opioid agonists, alpha adrenergic agonists, antihistamines including chlorpheniramine, prostaglandin blockers and antagonists, leukotriene blockers and antagonists, parasympathetic blockers and antagonists, interleukin blockers and antagonists, and nonsteroidal antiinflammatory agents including naproxen and ibuprophen. 12. A kit as recited in claim 8 wherein said antiviral agent is selected from the group consisting of inteferons, interferon inducers, capsid binding agents, benzoimidazoles, 1'-methyl spiro(adamantane-2,3-pyrrolidine)maleate, isatin thiosemicarbazone, fusidic acid, substituted trizainoindoles, 2,6-diphenyl-3-methyl-2,3-dihydroimidazo[2,1-b]thiazole, 3-alpha-naphthl-5-diethylcarbamoyl-1,2,4-oxadiazole, oxolinic acid, isoquinolines, 1-p-chlorophenyl-3-(m-3-isobutylguanidinophenyl)urea hydrochloride, anti ICAM-1 antibody and other viral receptor antibodies, synthetic ICAM-1 and other synthetic viral receptors, amantadine, rimantadine, and ribavirin. 13. A kit as recited in claim 8 further comprising a therapeutically effective amount of at least one antihistamine which is different from said antiinflammatory compound.

Details for Patent 5,422,097

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2012-06-06
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2012-06-06
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2012-06-06